Status: Not yet recruiting
A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
The purpose of this study is to confirm the efficacy and safety of pemigatinib in participants with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 fusion or rearrangements after at least 1 prior line of systemic therapy.
Participants needed: 72
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Incyte CorporationUpdated: Oct 7, 2026
Eligibility criteria
Histologically or cytologically confirmed unresectable, locally advanced or meta... [+6]
Prior treatment with any FGFR inhibitor for any indication. [+8]